Jefferies Ractchets Numbes on Biogen (BIIB) Higher Post Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Biogen (BIIB) Underpromise/Overdeliver Strategy Plays Well on Wall Street
July 25, 2013 10:55 AM EDTLeerink Swann today maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $271. Biogen reported strong Q2 results, with notable strength in Tecfidera. Meanwhile, sales of Tysabri appear to be suffering.
"We believe the strong 2Q13 quarter will lead... More
Biogen Idec, Inc. (BIIB) Tops Q2 EPS by 37c; Issues Solid Guidance
July 25, 2013 7:09 AM EDTBiogen Idec, Inc. (NASDAQ: BIIB) reported Q2 EPS of $2.30, $0.37 better than the analyst estimate of $1.93. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.62 billion.
Biogen Idec, Inc. sees FY2013 EPS of $8.25-$8.50, versus the consensus of $8.22.
Revenue gains were led by the performance of our marketed therapies:
AVONEX® revenues increased 2% year-over-year to $774 million. The total was comprised of $479 million in U.S.... More
